1,277 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Acquired by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC purchased a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) during the 2nd quarter, HoldingsChannel.com reports. The firm purchased 1,277 shares of the company’s stock, valued at approximately $207,000.

Other institutional investors have also bought and sold shares of the company. Capital Investment Advisory Services LLC grew its position in CRISPR Therapeutics by 9.0% in the second quarter. Capital Investment Advisory Services LLC now owns 22,613 shares of the company’s stock worth $3,661,000 after buying an additional 1,858 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in CRISPR Therapeutics by 15.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 45,433 shares of the company’s stock worth $7,355,000 after buying an additional 6,066 shares during the last quarter. Advisory Services Network LLC grew its position in CRISPR Therapeutics by 22.2% in the first quarter. Advisory Services Network LLC now owns 10,158 shares of the company’s stock worth $1,238,000 after buying an additional 1,848 shares during the last quarter. Commonwealth Equity Services LLC grew its position in CRISPR Therapeutics by 8.2% in the first quarter. Commonwealth Equity Services LLC now owns 30,140 shares of the company’s stock worth $3,672,000 after buying an additional 2,275 shares during the last quarter. Finally, Moneta Group Investment Advisors LLC acquired a new position in CRISPR Therapeutics in the first quarter worth approximately $432,000. Hedge funds and other institutional investors own 52.68% of the company’s stock.

Several research firms have issued reports on CRSP. TheStreet upgraded shares of CRISPR Therapeutics from a “d” rating to a “c+” rating in a research report on Monday, August 9th. Chardan Capital lowered their price objective on shares of CRISPR Therapeutics from $175.00 to $171.00 and set a “buy” rating on the stock in a research report on Friday, July 30th. Canaccord Genuity lifted their price objective on shares of CRISPR Therapeutics from $151.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, August 16th. upgraded shares of CRISPR Therapeutics from a “sell” rating to a “neutral” rating and lifted their price objective for the stock from $55.00 to $132.00 in a research report on Monday, June 14th. Finally, Citigroup upgraded shares of CRISPR Therapeutics from a “sell” rating to a “neutral” rating and lifted their price objective for the stock from $55.00 to $132.00 in a research report on Monday, June 14th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $160.00.

In other CRISPR Therapeutics news, Director Bradley J. Phd Bolzon sold 10,000 shares of the business’s stock in a transaction on Monday, July 19th. The shares were sold at an average price of $126.43, for a total transaction of $1,264,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, President Rodger Novak sold 25,000 shares of the business’s stock in a transaction dated Wednesday, June 30th. The stock was sold at an average price of $165.00, for a total transaction of $4,125,000.00. Following the transaction, the president now owns 573,007 shares in the company, valued at approximately $94,546,155. The disclosure for this sale can be found here. In the last three months, insiders have sold 106,875 shares of company stock valued at $15,362,110. Company insiders own 10.70% of the company’s stock.

CRSP stock opened at $116.30 on Wednesday. CRISPR Therapeutics AG has a 1 year low of $79.31 and a 1 year high of $220.20. The company has a fifty day simple moving average of $126.62 and a 200 day simple moving average of $124.38. The firm has a market cap of $8.86 billion, a PE ratio of 22.76 and a beta of 2.25.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Thursday, July 29th. The company reported $9.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.52 by $5.92. CRISPR Therapeutics had a net margin of 49.52% and a return on equity of 24.08%. The business had revenue of $900.70 million during the quarter, compared to analyst estimates of $678.05 million. Sell-side analysts anticipate that CRISPR Therapeutics AG will post 4.81 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Recommended Story: Risk Tolerance

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP).

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.